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Introduction: The kidneys are one of the main dose limiting organs in 177Lu-octreotate therapy of
neuroendocrine tumors. Therefore, biomarkers for radiation damage would be of great importance in this
type of therapy. The purpose of this study was to investigate the absorbed dose dependency on early
transcriptional changes in the kidneys from 177Lu-octreotate exposure.
Methods: Female Balb/c nude mice were i.v. injected with 1.3, 3.6, 14, 45 or 140 MBq 177Lu-octreotate. The
animals were killed 24 h after injection followed by excision of the kidneys. The absorbed dose to the kidneys
ranged between 0.13 and 13 Gy. Total RNA was extracted from separated renal tissue samples, and applied to
Illumina MouseRef-8 Whole-Genome Expression Beadchips to identify regulated transcripts after irradiation.
Nexus Expression 2.0 and Gene Ontology terms were used for data processing and to determine affected
biological processes.
Results: Distinct transcriptional responses were observed following 177Lu-octreotate administration. A higher
number of differentially expressed transcripts were observed in the kidneymedulla (480) compared to cortex
(281). In addition, 39 transcripts were regulated at all absorbed dose levels in the medulla, compared to 32 in
the cortex. Three biological processes in the cortex and ﬁve in the medulla were also shared by all absorbed
dose levels. Strong association to metabolism was found among the affected processes in both tissues.
Furthermore, an association with cellular and developmental processes was prominent in kidney medulla,
while transport and immune response were prominent in kidney cortex.
Conclusion: Speciﬁc biological and dose-dependent responses were observed in both tissues. The number of
affected transcripts and biological processes revealed distinct response differences between the absorbed
doses delivered to the tissues.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Therapy using radiolabeled somatostatin analogs has become a
novel approach for treatment of somatostatin receptor-overexpres-
sing neuroendocrine (NE) tumors. Successful results have been
shown in tumor regression, increased overall survival, and improved
quality of life for patients with different types of NE tumors [1,2].
Uptake of radiolabeled somatostatin analogs in normal tissues is
generally lower than in tumor tissue [3,4]. The highest normal tissue
uptake takes place in the kidneys via, e.g., active reabsorption of
radiolabeled octreotate in the proximal tubule of the nephron [5–8].hysics, Sahlgrenska University
3429695.
-NC-ND license.Uptake values of 5–7.7%IA/g have been reported in mice 24 h after
injection of 177Lu-octreotate, while lower values have been reported
in humans (after infusion of basic amino acids) [9–11]. Despite
blocking of kidney uptake, the kidneys are still one of the main dose
limiting organs when patients undergo therapy with 177Lu-octreo-
tate [12]. The routinely used kidney absorbed dose limit is taken
from experience from external beam radiation therapy with
nephropathy as endpoint [13]. However, data from external beam
therapy cannot be directly translated to radionuclide therapy, due to
the much lower dose rate, the continuous irradiation, and the
inhomogeneous dose distribution within the organs and body in
radionuclide therapy [14]. Since there is still limited knowledge on
normal tissue effects after radionuclide therapy, it is hard to deﬁne
tolerance doses to the kidneys for this application. Animal studies
have shown nephrotoxicity after injection with 90 MBq and 280–
560 MBq 177Lu-octreotate in mice and rats, respectively [8,15].
Furthermore, nephrotoxicity has also been shown clinically (early
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disease [12,14,16,17]. The latency times of acute and chronic
radiation-induced nephropathy vary. Acute nephropathy may be
induced after 6–12 months, while chronic nephropathy may be
induced up to 5 years after therapy. Therefore, it is important to
monitor renal function over long time periods after therapy [14].
There is a need for a better understanding of the biological
response following irradiation of the kidneys with 177Lu-octreotate,
to minimize side effects and, if possible, to enlarge the therapeutic
window and success rate [18]. Gene expression analysis using
microarray technology has the ability to provide a comprehensive
view of the biological effects after exposure to ionizing radiation.
This technique allows for a direct whole genome, transcriptome, and
proteome investigation of the cellular responses to radiation.
Microarray analysis has been employed successfully to elucidate
the effects on normal tissues and to develop a deeper understanding
of the potential molecular targets and biological events initiated in
irradiated tissue [19,20]. Nevertheless, only a few studies using
global gene expression analysis of irradiated kidneys have been
published, which predominantly used external irradiation of animal
models [19–21]. To our knowledge there are only two reports on
global gene expression studies following internal irradiation of the
kidneys [22,23]. These studies showed a clear response of the kid-
neys from very low absorbed doses (0.20–3.5 mGy) of 131I and
0.24–160 mGy of 211At at 24 h after injection [22,23]. However,
further studies are needed to better understand the biological re-
sponse of radiation as a basis for deﬁning possible clinically useful
biomarkers for early radiation nephrotoxicity.
The aim of this study was to investigate early transcriptional
response in kidney cortex and medulla after i.v. injection of different
amounts of 177Lu-octreotate in mice.
2. Materials and Methods
2.1. Radiopharmaceutical
177LuCl3 and DOTA-Tyr3-octreotate were acquired from I.D.B.
Holland (I.D.B. Holland BV, Baarle-Nassau, Netherlands). Preparation
and radiolabeling were conducted according to the manufacturer’s
instructions. Instant thin layer chromatography (ITLC) revealed that
the fraction of peptide bound 177Lu was higher than 99%. The 177Lu-
octreotate stock solution was diluted to the ﬁnal activity concentra-
tions with saline solution.
Before and after administration, the 177Lu activity in the syringes
was measured with a well-type ionization chamber (CRC-15R;
Capintec, IA, USA) to determine the injected activity in each animal.
2.2. Animals
Female BALB/c nude mice (Charles River, Salzfeld, Germany) were
divided into six groups with three animals in each and were kept
under normal nutritional conditions. Five groups were i.v. injected
with 1.3, 3.6, 14, 45, and 140 MBq 177Lu-octreotate (0.04 μg
octreotate/MBq), while the control group was i.v. injected with saline
solution. The experimental protocol was approved by the Ethical
Committee on Animal Experiments in Gothenburg, Sweden.
Twenty-four hours after injection the animals were killed by car-
diac puncture under anesthesia (pentobarbitalnatrium, APL, Sweden)
and the kidneys were surgically removed. One kidney from each
animal was immediately ﬂash frozen in liquid nitrogen and stored at
−80 °C until analysis. The remaining kidney was weighed and the
177Lu activity was measured with a gamma counter (Wallac 1480
Wizard, Wallac Oy, Turku, Finland). The gamma counter was cali-
brated against the ionization chamber. Corrections were done for
background signal and dead time effects.2.3. Dosimetry
Estimations of the absorbed dose to the kidneys were made ac-
cording to the Medical Internal Radiation Dose (MIRD) formalism [24]:
DKidney ¼ A˜Kidney ∑niEiϕi=mKidney ;
where ÃKidney is the cumulated activity during the ﬁrst 24 h after
injection
A˜Kidney ¼ ∫24h0 Akidney tð Þdt ;
the product niEi is the average energy emitted by electrons per decay,
ϕi is the absorbed fraction and mKidney is the mass of the kidney
investigated. Values for Ãtissue were estimated based on previously
published biodistribution data of 177Lu-octreotate in nude mice
together with the activity concentration measurements of the re-
moved kidneys in the present study [10]. A mono-exponential curve
was ﬁtted to the time-activity concentration data obtained. The
integral of the ﬁtted equation was calculated for 0–24 h to estimate
the cumulated activity. The absorbed fraction, ϕi, was assumed to be
0.93 [25]. Only the contribution from the electronswas included in the
dosimetric calculations. The absorbed dose was determined for the
whole kidney.
2.4. RNA extraction and analysis
The ﬂash-frozen kidneys were dissected into cortical and medul-
lary tissues and homogenized using the Mikro-Dismembrator S ball
mill (Sartorius Stedim Biotech). Total RNA was extracted using the
RNeasy Lipid Tissue Mini Kit (Qiagen), according to the manufacturer´
s instructions. RNA Integrity Number (RIN) values were retrieved
using RNA 6000 Nano LabChip Kit with Agilent 2100 Bioanalyzer
(Agilent Technologies) and samples with RIN values above 6.0 were
accepted for further analysis (lowest RIN value in the present study
was 6.6 with a mean value of 8.2).
Processing of the RNA samples was conducted at the Swegene
Center for Integrative Biology at Lund University (SCIBLU). MouseRef-
8Whole-Genome Expression Beadchips (Illumina), containing 25,435
probes were used for hybridization. Image acquisition and subsequent
analysis were performedwith Illumina BeadArray Reader scanner and
BeadScan 3.5.31.17122 image analysis software, respectively.
2.5. Data processing and statistical analysis
Data preprocessing and quantile normalization of raw signal in-
tensities were conducted through the use of the web-based BioArray
Software Environment (BASE) system. Nexus Expression 2.0 (BioDis-
covery) was used for further analysis with log2-transformed, nor-
malized expression values and a variance ﬁlter.
To determine differentially expressed transcripts and to control
the false discovery rate, the Benjamini–Hochberg method was used
[26]. A p-adjusted value of 0.01 and a fold change of at least 1.5 (up- or
down-regulation) were considered statistically signiﬁcant. Generated
gene expression proﬁles are displayed at NCBI´s Gene Expression
Omnibus (GEO accession number GSE44762).
Gene Ontology (GO) terms were used to determine affected
biological processes (the biochemical reactions, known to be regu-
lated by the genes whose expression was affected) from differen-
tially regulated gene sets using two separate approaches. First, GO
terms were determined in Nexus Expression, employing a p value
cutoff of 0.05. However, 40% of the ﬁltered Illumina transcripts
are not assigned to a known biological process. Therefore, a com-
plete listing of annotated genes was compiled for differentially
regulated transcripts using the Gene Ontology website (http://www.
geneontology.org/). Using this list, transcripts with a log2-ratio
Table 1
Number of differentially regulated transcripts in the kidney cortex and medulla.
Number of regulated transcripts in kidney cortex and medulla is shown for each
absorbed dose, compared to either non-irradiated controls or a lower dose level.
The number of up/down regulated transcripts is indicated in green/red.
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gorized into eight main GO categories and further subcategories:
DNA integrity, cell communication, cell cycle and differentiation,
cellular integrity, gene expression integrity, metabolism, organismic
response, and stress response.
2.6. Quantitative real-time PCR (QPCR)
To verify the microarray results, nine signiﬁcant differentially
expressed genes detected in both renal tissues at all absorbed dose
levels (Angpti4, Cyp24a1, Dnase1, Gldc, Hmgcs2, Igfbp4, S100a8,
Slc25a20, and Slc25a25) were selected and scrutinized using the
quantitative real-time polymerase chain reaction (QPCR) assay.
Another three constitutive genes (B2m, Gusb, and Ywhaz), which
showed homogenous expression through the microarray analysis
were used for normalization. Commercially available validated Taq-
Man® Gene Expression Assays were obtained from Applied Biosys-
tems (Carlsbad, CA, USA). For each specimen cDNA was synthesized
from 1 μg total RNA (the same RNA extraction as in the microarray
experiments) using SuperScript™ III First-Strand Synthesis SuperMix
for qRT-PCR (Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer´s protocol. The standard curve method was used for quan-
tiﬁcation and the geometric mean of the three endogenous controls
(B2m, Gusb, and Ywhaz) was used for normalization of the samples.
The Pearson correlation coefﬁcient was used to calculate the corre-
lation between the microarray and the QPCR results.
3. Results
3.1. Dosimetry
The absorbed doses to the kidneys were estimated to 0.13, 0.34,
1.3, 4.3, and 13 Gy during 24 h after injection of 1.3, 3.6, 14, 45, and
140 MBq 177Lu-octreotate, respectively. The absorbed dose estimat-
ed to inﬁnity time would correspond to 0.31, 0.85, 3.3, 11, and
32 Gy, respectively.
3.2. Differentially regulated transcripts
A clear biological response at the transcriptional level was seen in
both kidney cortex and medulla following administration of 177Lu-
octreotate. In total, 281 and 480 differentially regulated transcripts
were detected in the kidney cortex and medulla, respectively.
In kidney cortex, the number of regulated transcripts varied with
absorbed dose. The highest number of regulated transcripts com-
pared to control was found at 4.3 Gy (180 transcripts), with a reduc-
tion in the number of regulated transcripts at both higher and lower
absorbed doses (Table 1). When comparing differences and similar-
ities between exposed groups, few common transcripts were seen
between 1.3 and 13 Gy, with only 6 transcripts. With the exception of
the 80 differentially expressed transcripts between 4.3 and 13 Gy, the
number of differentially expressed transcripts increased with in-
creased difference in absorbed dose.
The fraction of dose-speciﬁc regulated transcripts in the kidney
cortex was around 30% for 0.13, 4.3, and 13 Gy, while for 0.34 and
1.3 Gy this number was reduced to 6% and 12%, respectively (Table 2).
In kidney medulla, the highest number of regulated transcripts
was found at 1.3 Gy (348 regulated transcripts). For both higher and
lower absorbed doses, the number of regulated transcripts was clearly
reduced, e.g. 147 at 0.34 Gy and 205 at 4.3 Gy. At the other dose levels,
143 (0.13 Gy) and 130 (13 Gy) regulated transcripts were detected
(Table 1). In the comparison of the inter-dose response, a prominent
difference could be seen between 0.34 and 1.3 Gy, 1.3 and 13 Gy, as
well as between 1.3 and 4.3 Gy with 422, 364, and 282 differentially
expressed transcripts, respectively, while the difference in response
between 0.13 and 0.34 Gy was weak (27 differentially regulatedtranscripts). In addition, no increase in number of differentially regu-
lated transcripts could be seen with increasing difference in absorbed
dose (Table 1). The increased number of regulated transcripts at
1.3 Gy resulted in a higher fraction of unique transcripts (47%) regu-
lated at this speciﬁc dose level (Table 2).
In total, 32 and 39 transcripts were regulated in all irradiated
groups for kidney cortex and medulla, respectively (Table 3). Among
these, 22 transcripts were shared by both tissues. Of these 49 tran-
scripts, the UniGene repository showed that 69% and 72% in kidney
cortex and medulla, respectively, are normally expressed in the
mouse kidney, while three transcripts could not be found in the
repository. The regulation proﬁles vs. injected activity showed large
variations between the different transcripts. In general, the expres-
sion variation of the majority of the analyzed transcripts was rela-
tively similar irrespective of absorbed dose. The only obvious
monotonous dose–response relationship was found for Hmgcs2,
with very high up-regulation after exposure to the lowest absorbed
dose, and decreasing expression with increased absorbed dose for
both kidney cortex and medulla. Similar proﬁles were also found for
Igfbp4 in kidney cortex. Angptl4 (angiopoietin-like 4) showed a
constant expression in both cortex and medulla at all but the highest
absorbed dose, where a reduced expression was found. Cyp24a1
(Cytochrome P450) showed a very strong expression in the 14 MBq
group in both kidney cortex and medulla, with reduced expression at
the other dose levels investigated.
Transcripts with log2-ratio above 2, for either positive or negative
regulation, are presented in Table 4. Few transcripts had log2-ratios
above 2: 21 transcripts in the cortex and 13 in the medulla. In both
tissues, enriched transcripts were generally involved in cell cycle and
differentiation at the highest dose level (13 Gy), stress responses at
the intermediate dose levels (1.3 and 4.3 Gy), and cellular integrity at
the lowest absorbed dose level (0.13 Gy). In addition, regulated
transcripts related to metabolism were seen at all but the highest
dose levels. No genes with regulated expression above/below this
threshold (log2-ratio N 2 or b 0.5, respectively) were found to be
associated with gene expression integrity, cell communication, or
organismic regulation.
Table 2
Distribution of common and dose-speciﬁc differentially regulated transcripts.
The total number of uniquely (rows 1–5) or commonly (rows 6–31) regulated transcripts for one or more absorbed doses is given in columns 6 and 12 for the kidney cortex and
medulla. The distribution of differentially expressed transcripts per absorbed dose is given as percentage of the total number of regulated transcripts per absorbed dose level.
The total number of regulated transcripts per dose level compared to controls is given in parenthesis. The percentage of scored transcripts is color coded according to strength
of regulation.
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tissues at all dose levels using QPCR. The two methods (microarray
and QPCR) showed strong correlation (r N 0.85) for all genes tested
(Angpti4, Cyp24a1, Dnase1, Gldc, Hmgcs2, Igfbp4, S100a8, Slc25a20,
and Slc25a25).
3.3. Affected biological processes
A total of 91 biological processes were affected by the adminis-
tration of 177Lu-octreotate in both kidney cortex and medulla, but the
type of processes as well as the occurrence at each absorbed dose level
differed (Figs. 1 & 2, Supplementary Table S1 & S2). Kidney medulla
had a higher number of biological processes affected at the highest
absorbed dose compared to kidney cortex (32 vs. 22). At 1.3 and
4.3 Gy, kidney cortex had a higher number of affected biologicalprocesses compared to kidney medulla (40 and 41 vs. 23 and 34,
respectively). A similar number of affected biological processes were
found for the two tissues at the two lowest dose levels.
In both tissues, the affected biological processes were strongly
associated with metabolic processes at all dose levels, with the
strongest association found at the lowest dose level (0.13 Gy) (Figs. 1
& 2, Supplementary Table S1 & S2). The association with metabolic
processes was lower at the higher absorbed doses as a result of a
reduction of processes associated with the metabolism of proteins/
amino acids and lipids/fatty acids. Regulation of carbohydrate meta-
bolism included a heterogeneous mixture of various biological
processes, but the total number of regulated processes remained on
a similar level at all absorbed doses.
In both tissues, immune response was the predominantly affected
subcategory of stress responses. The highest impact was found at 1.3
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regulation of immune response and positive regulation of T cell
differentiation. No biological processes associated with DNA integrity
were observed for either tissue and an effect on gene expression
integrity was only observed in the kidney medulla. (Figs. 1A & 2A,
Supplementary Table S1 & S2).
Immune response, as a speciﬁc biological process, was the only
process affected at all absorbed doses and in both tissues. However,
the strength of the response differed between the tissues. In kidney
cortex and medulla, 23 and 34 genes were regulated at one or more
dose levels, respectively. In medulla, a higher number of regulated
genes associated with immune response were found at all dose levels,
compared to cortex (6 vs 2). The two regulated genes (Serpina3g and
Tgtp) in the cortex were also regulated in medulla. Serpina3g is
associated with apoptosis, regulation of proteolysis, and response to
cytokine stimulus, whereas Tgtp is associatedwith cellular response to
interferon-beta.
4. Discussion
Normal tissue exposure to radiation is inevitable during radionu-
clide therapy. Consequently, radiation-induced normal tissue effects
set the limit for the radionuclide activity that can safely be
administered, and hence the absorbed dose to tumor tissue. 177Lu-
octreotate therapy has shown great promise in the treatment of
neuroendocrine tumors. One of the main critical organs for 177Lu-
octreotate therapy of neuroendocrine tumors is the kidneys. In the
present study, the transcriptional effects of 177Lu-octreotate irradia-
tion on cortical and medullary kidney tissues were investigated in
non-tumor bearing mice in an attempt to increase our understand-
ing of the early response in kidneys during this type of therapy. These
effects were studied using gene expression microarray analysis,
where the entire mouse transcriptome was investigated to identify
differentially expressed transcripts and affected biological processes.
Strong biological response, both general and tissue-speciﬁc, was seen
in both kidney cortex and medulla.
There are large individual variations in absorbed dose to the kid-
neys per fraction in patients undergoing 177Lu-octreotate therapy,
with values of 0.33–2.4 Gy/GBq (corresponding to 2.4–17 Gy per
fraction) [11]. In order to have clinically relevant absorbed doses in the
present study, the injected activities of 14 and 45 MBq, corresponding
to absorbed doses of 3.3 and 11 Gy when estimated to inﬁnity, were
chosen. The highest absorbed dose in the present study was 13 Gy
delivered over 24 h. However, the estimated absorbed dose to inﬁnity
time would correspond to 32 Gy, where the risk of nephrotoxicity
would be present [13]. Finding early biomarkers for kidney toxicity is
of highest concern to optimize individualized patient treatment. This
study represents one step towards ﬁnding novel early biomarkers for
kidney toxicity, but also presents data that may lead to a better
understanding of themechanisms behind radiation induced effects on
kidney tissue. In future studies, the early transcriptional effects should
be compared to those of later time points, as well as functional and
morphological effects, in order to ﬁnd possible correlation between
early indicators/biomarkers and late toxicity.
The absorbed dose calculations were carried out using activity
concentration measurements of the kidneys in the present study
and previously published data [10]. The mice in the biodistribution
study were tumor bearing and it was assumed that the presence of
tumors did not inﬂuence the 177Lu concentration in the kidneys due
to limited uptake in tumor tissue (0.23%IA/g in tumor vs. 6.2%IA/g in
kidney at 24 h). Furthermore, the uptake in kidney tissue is highly
heterogeneous, with highest accumulation taking place in the kidney
cortex, whereas the concentration in the outer medulla corresponds
to 50%–60% of the cortical activity [27]. In addition, the cortical
uptake is also heterogeneous, with the highest accumulation taking
place in the proximal tubules, with very low amounts detected in thedistal tubules and the glomeruli [27–29]. However, due to the small
size of the mouse kidney, together with the relatively long range of
the beta particles emitted by 177Lu (maximum range in water:
1.6 mm), a relatively homogenous dose distribution was assumed.
Therefore, the differences in the transcriptional variations of the two
tissues (kidney cortex and medulla) observed in the present study
are assumed to depend on the differences of the analyzed tissues, and
not on possible differences in the radiation parameters. A previous
study using 131I detected differences in the response between kidney
cortex and medulla [22]. Similar tendencies as in the present
investigation were observed with increased number of regulated
transcripts in kidney medulla as compared to kidney cortex.
Furthermore, the detected response in the present study is
considered to depend on the properties of the irradiation, and not
on the somatostatin analogue itself. We have previously found that
only minor transcriptional variations are induced in the kidneys 24 h
after administration of octreotate (Schüler et al., unpublished data).
A comparison of the detected differentially regulated transcripts
in the kidney cortex and medulla showed both tissue-speciﬁc and
common regulations. However, the response in the kidney medulla at
1.3 Gy was surprisingly strong. At this dose level, the number of
uniquely regulated transcripts was 8 times higher than what was
observed at both higher and lower absorbed doses (163 vs. 18–22
uniquely regulated transcripts). In addition, among the uniquely
regulated transcripts identiﬁed at 1.3 Gy, 82% were up-regulated,
which accounts for the substantial differences seen between the
kidney cortex and medulla at this dose level. The reasons for this
deviation speciﬁcally at 1.3 Gy is not known, but similar overall
results have been obtained in the thyroid in vivo after 1.4 Gy expo-
sure to 211At [30]. In that study, we stipulated that the biological
response does not only vary in magnitude but also in the fundamen-
tal response at various absorbed doses. Additionally, we suggested
that a strong response was observed when the absorbed dose is high
enough to impose severe cellular damage but low enough to allow
repair. Since 211At is an alpha emitter with high RBE, a similar effect
for 177Lu would be expected at higher absorbed doses. However, a
direct comparison is not possible due to the differences in tissue type
and radionuclide properties.
Signiﬁcant differences among affected biological processes were
seen between higher and lower absorbed doses, e.g. increased asso-
ciation with stress response and a reduced association with metabolic
processes with increasing absorbed dose. However, this trend is
reduced when assessing the number of uniquely regulated genes per
biological process and absorbed dose. A higher number of stress
response associated genes were detected at most absorbed doses
compared to those associated with metabolism. Also, the difference
seen between metabolism compared to the other categories, e.g. cell
communication, cell cycle and differentiation, cellular integrity, and
gene expression integrity, was lower when assessing only the num-
ber of uniquely regulated genes, as opposite to the number of affected
biological processes. However, the impact of this difference on these
higher levels of cellular functions is unknown and larger studies with
larger number of time points and inclusion of functional data is
needed in order to elucidate these results.
One of the main molecular lesions induced by ionizing radiation is
DNA damage. While processes associated with cell cycle regulation and
cell death were affected in this study, indicating DNA damage, no
processes were found to be associated with maintenance of DNA
integrity andonly a fewprocesseswere associatedwith gene expression
integrity. This could be explained by inadequate information or artifacts
in the ontology. However,while it is known from in vitro studies that the
transcriptional response after genotoxic stress affects processes associ-
atedwith cell cycle regulation and DNA repair, a more general response
is also usually observedwithmodulation of cell-death pathways, energy
metabolism, cell–cell communication and RNA processing, making the
response to genotoxic stress very diverse [31–33]. Furthermore,
Table 3
Regulated transcripts in common at all dose levels after 177Lu-octreotate exposure in nude mice.
(continued on next page)
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Table 3 (continued)
Gene symbols and gene expression log2 ratios for the differentially expressed transcripts identiﬁed at all absorbed dose levels for kidney cortex and medulla. The normal
expression of these genes in kidney tissue is presented according to Unigene. Red corresponds to down-regulation and green to up-regulation, and the intensity in color
corresponds to the degree of regulation.
Explanation of denotation: Yes, mRNA levels found in normal tissue; NA, data not available; −, gene not found.
a Mouse gene expression data from Unigene.
244 E. Schüler et al. / Nuclear Medicine and Biology 41 (2014) 238–247processes such as glycolysis/gluconeogenesis and synthesis/degrada-
tion of ketone bodies, oxidative phosphorylation, Rho-mediated cell
motility, and non-homologous end joining have been found affected by
irradiation of speciﬁcally epithelial cells in vitro [34]. This diversity is also
reﬂected by the results presented in this study, potentially related to
genotoxic stress induced by the radiation exposure. However, single cell
analysis comparing different cell types may separate the renal cell type
response from other epithelial and vascular cell type response. Thus, the
effects demonstrated in the present study represent the combined
effects from all cells and cell types in the tissue analyzed.
Previously, gene expression proﬁles have been investigated and
altogether 93 potential biomarkers for radiation exposure have beenTable 4
Gene Ontology enriched terms for transcripts with a log2-ratio above 2.
Tissue Absorbed dose Cell cycle and
differentiation
Stress response Cellular
integrity
Cortex 0.13 Gy Angptl4 Slc7a12
Ucp1
0.34 Gy
1.3 Gy H2-Ab1
Angptl4
4.3 Gy Phlda3 H2-Ab1
H2-Ea
H2-Eb1
Cd74
Igtp
Gbp1
H2-DMb1
Angptl4
13 Gy Ccng1 Ephx1 Actg2
Cdkn1a
Phlda3
Medulla 0.13 Gy Ucp1
0.34 Gy Lcn2
1.3 Gy Igtp
Cfd
4.3 Gy Igtp
Lcn2
H2-Ab1
Scgb1a1
13 Gy Phlda3
Cdkn1a
Differentially expressed transcripts with log2-ratio ≥ 2, either positive or negative regulatioidentiﬁed [22,30,35–37]. In our data set, only seven of these 93 genes
were regulated in kidney cortex. These seven genes were regulated at
the highest dose level (13 Gy), while 0, 0, 2, and 3 genes were
regulated for the dose levels 0.13, 0.34, 1.3, and 4.3 Gy, respectively,
with some genes regulated at more than one absorbed dose level. In
kidney medulla, 12 of the 93 genes were found regulated with 1, 1, 6,
4, and 6 gene(s) regulated at the dose levels 0.13, 0.34, 1.3, 4.3, and
13 Gy, respectively. No genes were regulated at more than three dose
levels and only two genes were regulated at three dose levels, both in
kidney cortex and in medulla: Ccng1 and Cdkn1a, both involved in
regulation of cyclin-dependent protein and kinase activity. Further-
more, some genes have been proposed to be consistently regulatedMetabolism Gene expression
integrity
Cell
communication
Organismic
regulation
Serpina10
Hmgcs2
Hmgcs2
Pck1
Cyp24a1
Serpina10
Hmgcs2
Hmgcs2
Pck1
Cyp24a1
Car3
Igf2
n for the different tissues, absorbed dose levels, and according to gene function.
Fig. 1. Affected biological processes and uniquely regulated transcripts in kidney cortex. Number of affected biological processes (A) for each absorbed dose in kidney cortex after
injection of 1.3–140 MBq 177Lu-octreotate categorized according to higher level cellular function. The number of uniquely regulated genes for each category per absorbed dose is
shown in (B).
245E. Schüler et al. / Nuclear Medicine and Biology 41 (2014) 238–247after both high and low absorbed doses. In the present study Cdkn1a
was only regulated at 1.3 to 13 Gy, not at the lower absorbed doses.
Gadd45 (growth arrest and DNA-damage-inducible 45 beta), which
has been found to be frequently regulated after radiation therapy [35],
was not detected in our data sets, not even at the higher absorbed
dose levels. These ﬁndings illustrate the differences in results ob-
tained between different cell lines as well as between different tissue
types, but also between in vivo vs. in vitro studies, since the proposed
genes have predominantly been identiﬁed in in vitro studies.
Studies investigating whole transcriptional response following
internal irradiation are few. Our group has previously found a strong
association with metabolic processes after low dose 131I and 211At
irradiation of the kidneys [22,23]. The present results strengthen the
conclusion that irradiation of kidney tissue with low absorbed doses
primarily has an impact on basal metabolic processes.
Other studies have investigated changes in gene expression pat-
terns following acute or chronic external irradiation of the kidneys.
Zhao and colleagues demonstrated the gene expression proﬁles of the
kidneys 8 h and 24 h after 10 Gy 137Cs whole body irradiation (4Gy/
min) [21]. Although a lower number of genes were found regulated
(42 genes), compared to the present study, the strongest responseFig. 2. Affected biological processes and uniquely regulated transcripts in kidney medulla.
after injection of 1.3–140 MBq 177Lu-octreotate categorized according to higher level cellular
is shown in (B).involved genes were associated with transcription, translation, and
metabolism. In the present study, few processes were associated with
gene expression integrity, while a strong association with metabo-
lism was found. However, no common genes associated with meta-
bolism were detected by Zhao and colleagues and the present study.
The discordance between the study from Zhao et al. and the present
study can be due to several factors, such as differences in mouse
strain, the type of irradiation (radionuclide, absorbed dose, dose rate,
etc.), as well as differences in the microarray platforms. In this study,
the Illumina whole transcriptome microarray platform was used,
while the previous study used other platforms containing fewer
probes, which might result in the detection of fewer regulated
transcripts. Another very important difference is the potential sys-
temic effects from other irradiated tissues [38], where whole body
irradiation will give similar absorbed dose to all tissue types, while in
the present study, non-kidney tissue types will receive a much lower
absorbed dose than the kidneys, which increases the possibility of
ﬁnding kidney-speciﬁc transcript regulation in the present study.
The dose–response relationship for a suitable single biomarker
for toxicity is preferably a function with a monotone increase or
decrease with absorbed dose. In the present investigation, few speciﬁcNumber of affected biological processes (A) for each absorbed dose in kidney medulla
function. The number of uniquely regulated genes for each category per absorbed dose
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increased absorbed dose. The majority of the affected transcripts
revealed little or no difference in response between the different
absorbed dose levels. The only exception was increasing down
regulation of the expression of the Hmgcs2 gene with increasing
absorbed dose after an up-regulation at the lowest dose level studied.
TheHavcr1 (hepatitis A virus cellular receptor 1) genewas differentially
expressed at all absorbed doses in kidney cortex, and has previously
been proposed as a predictor of kidney tubular damage, and its
corresponding protein is measurable in urine [39,40]. However, genes
that only show strong regulation at the higher absorbed doses may also
prove to be a desired relationship. The Cdkn1a gene showed a strong
increase in gene expression regulation in kidney cortex between the 4.3
(log2-ratio 1.5) and 13 Gy (log2-ratio 2.4) dose levels. Similar increase
but withweaker regulationwas found in kidneymedulla. This gene has
previously been proposed as biomarker for ionizing radiation as well as
acute kidney injury [35,36,41]. The Gdf15 gene also showed interesting
expressionwithdown-regulation at the lower absorbeddoses (0.13 and
0.34 Gy) with subsequent increase in up-regulation with increasing
absorbed dose for 1.3-13 Gy in both kidney cortex and medulla.
However, the change in expression of this gene was only signiﬁcant at
the highest absorbed dose (13 Gy) for both tissues. This gene has also
been proposed as a potential biomarker for kidney injury [41]. The
regulation of the expression of these genes, and other with similar
response, may also hold a desired dose–response relationship with the
function of reﬂecting major risk for toxicity.
The regulation of expression of one speciﬁc gene may, however,
not be adequate for the use as biomarker for kidney injury after
radiation exposure, due to the complex response of the injury pro-
gression [42]. Rather, the expression pattern of several genes may
prove to be more useful, where the expression of certain genes at
speciﬁc absorbed dose levels, as well as time, should be considered in
more detail. This type of analysis will be performed when more data
has been obtained.
To our knowledge, none of the genes which demonstrate sig-
niﬁcantly regulated expression at all absorbed doses in the present
study have previously been proposed as a biomarker for kidney
response to radiation. However, in mice 24 h after 131I administration,
the Cyp24a1 (Cytochrome P450) gene expression was up-regulated
whereas the Serpina10 (Serpin peptidase inhibitor) and the Havcr1
(hepatitis A virus cellular receptor 1) gene expressions were down-
regulated at all absorbed doses in kidney cortex studied (0.17–
3.5 mGy) [22]. Furthermore, in mice 24 h after 211At administration,
the Angptl4 (Angiopoietin-like 4) gene expression was up-regulated
at all absorbed doses in both kidney cortex and medulla (0.24–
160 mGy) [23]. Thus, indications of similar responses after adminis-
tration of different radionuclides in vivo exist. However, a deeper
analysis of the combined results of these studies is needed in order to
draw any ﬁrm conclusions regarding the similarities and differences
due to different radiation types.
5. Conclusion
The use of 177Lu-octreotate treatment of neuroendocrine tumors
is rapidly rising. Due to the low cure rate and that kidneys is the main
dose-limiting organ, more information on the molecular pathways
and biological processes associated with kidney response to ionizing
radiation is needed, information that is of great importance in the
search of clinically useful biomarkers in preferably urine or blood. This
study demonstrates distinct differences in the biological response
obtained after different absorbed doses. However, the impact of these
biological responses over longer time periods is still unknown.
Therefore, further research is needed to evaluate late biological
effects and correlate these to the risk of long-term or chronic side
effects after 177Lu-octreotate treatment, as one of several steps
towards patient-speciﬁc treatment.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nucmedbio.2013.12.001.Acknowledgments
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